Docoh
Loading...

TOMDF Todos Medical

Employees

Data from SEC filings
Employee count

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM


On July 26, 2021, Todos Medical Ltd. (the “Company”) held its annual general meeting of shareholders (the “Annual Meeting”). A total of 228,126,664 ordinary shares, constituting a quorum, were represented in person or by valid proxies at the Annual Meeting. The final results for each of the matters submitted to a vote of stockholders at the Annual Meeting, as set forth in the Proxy Statement, filed with the Securities and Exchange Commission on June 28, 2021 are as follows:

Proposal 1. The resolution to amend the Company’s Articles of Association: (a) to authorize the creation of 50,000 (fifty thousand) redeemable Preferred A Shares of the Company; (b) to authorize the creation of five thousand (five thousand) redeemable Preferred B Shares of the Company; (c) to increase the Company’s authorized share capital to permit the issuance of a total of up to 5,000,000,000 (five billion) ordinary shares of the Company; and (d) to allow the Company to fulfill relevant provisions of U.S. law in lieu of Israeli law requirements regarding External Directors, if and to the extent allowed to do so under Israeli corporate law and regulation was approved by the stockholders by the votes set forth in the table below:

ForAgainstAbstainBroker Non Vote
191,649,30129,860,2886,617,075


Proposal 2. The compensation packages recommended by the Compensation Committee and approved by the Board, including compensation for each of the Company’s currently serving Directors and C-level officers, as well as for the External Directors to be elected at the Annual Meeting was approved by the stockholders by the votes set forth in the table below:

ForAgainstAbstainBroker Non Vote
201,341,35423,680,3833,104,927


Proposal 3. The election of Lauren Chung as an External Director of the Company for a term ending on July 26, 2024 and the election of Moshe Schlisser as an External Director of the Company for a term ending July 26, 2024 was approved by the stockholders by the votes set forth in the table below:

ForAgainstAbstainBroker Non Vote
209,278,39514,070,5504,777,719




Proposal 4. The re-election of Gerald Commissiong, Dr. Herman Weiss, Daniel Hirsch and Moshe Abramovitz as directors of the Company was approved by the stockholders by the votes set forth in the table below:

ForAgainstAbstainBroker Non Vote
206,671,78115,938,5535,516,330


-2-


Proposal 5. The extension for an additional year the authority granted to the Company’s Board of Directors to effect a reverse split of the Company’s ordinary shares (as per resolution of the Company’s Shareholders’ Meeting of May 11, 2020), such that the authority so granted shall extend until July 26, 2022, and to expand such authority to include a reverse split of the Company’s entire share capital share at a ratio within the range from 1-for-2 up to 1-for 500, provided that the Company shall not effect reverse share splits that, in the aggregate, exceed 1-for-500 was approved by the stockholders by the votes set forth in the table below:

ForAgainstAbstainBroker Non Vote
197,642,46530,156,329327,870




Proposal 6. The adoption of the Company’s 2021 Equity Incentive Plan was approved by the stockholders by the votes set forth in the table below:

ForAgainstAbstainBroker Non Vote
201,966,47420,288,5555,871,635


Proposal 7. The appointment of Yarel and Company as the Company’s Auditors for the 2021 financial year was ratified by the stockholders by the votes set forth in the table below:

ForAgainstAbstainBroker Non Vote
210,259,19511,335,0656,532,404


-3-